glp-1 and type 2 diabetes The activity of GIP for and Obesity GLP-1 receptor agonists | How

MH is the guarantor of this work and, as such, had full access to data from the study and takes responsibility for the integrity of the data and accuracy of the data analysis

In 2025, insurance coverage became increasingly restrictive: The rollbacks were happening everywhere at once: Independence Blue Cross stopped covering GLP-1s for weight loss

doi:10.1016/j.amjmed.2025.01.021 Meloni AR, DeYoung MB, Lowe C, Parkes DG

Experimentation under medical guidance can identify the optimal timing for individual patients

The FDA approves GLP-1 for adults with BMI of 30 or higher, or BMI of 27 or higher with weight-related conditions like diabetes, hypertension, or sleep apnea